New complex polycyclic compounds: Synthesis, antiproliferative activity and mechanism of action.

Antiproliferative activity Apoptosis Autophagy MDA-MB231 breast cancer cells O-glycoconjugate polycyclic compounds Pyrazolo[3,4-b]pyrazolo[3′,4′:2,3]azepino[4,5-f]azocine

Journal

Bioorganic chemistry
ISSN: 1090-2120
Titre abrégé: Bioorg Chem
Pays: United States
ID NLM: 1303703

Informations de publication

Date de publication:
08 2020
Historique:
received: 18 02 2020
revised: 25 04 2020
accepted: 29 05 2020
pubmed: 21 6 2020
medline: 30 3 2021
entrez: 21 6 2020
Statut: ppublish

Résumé

Polycyclic or O-glycoconiugate polycyclic compounds 1a-g were previously tested for their in vitro antiproliferative activity. In this series of compounds, activity increases as log P decreases. Specifically, compounds 1d and 1g showed lower log P values together with the best antiproliferative profiles. With the aim of extending our understanding of the structure-activity relationship (SAR) of this class of compounds, we prepared new polycyclic derivatives 2a-c, which bear on each of the two phenyl rings hydrophilic substituents (OH, SO

Identifiants

pubmed: 32563004
pii: S0045-2068(20)31286-4
doi: 10.1016/j.bioorg.2020.103989
pii:
doi:

Substances chimiques

Polycyclic Compounds 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, P.H.S.

Langues

eng

Sous-ensembles de citation

IM

Pagination

103989

Subventions

Organisme : NCI NIH HHS
ID : HHSN261200800001E
Pays : United States

Informations de copyright

Copyright © 2020 Elsevier Inc. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Auteurs

Giuseppe Daidone (G)

Department of Biological, Chemical and Pharmaceutical Sciences and Technologies (STEBICEF), Medicinal Chemistry and Pharmaceutical Technologies Section - University of Palermo, Via Archirafi 32, 90123 Palermo, Italy.

Antonella D'Anneo (A)

Department of Biological, Chemical and Pharmaceutical Sciences and Technologies (STEBICEF), Laboratory of Biochemistry, University of Palermo, Via del Vespro 129, 90127 Palermo, Italy.

Maria Valeria Raimondi (MV)

Department of Biological, Chemical and Pharmaceutical Sciences and Technologies (STEBICEF), Medicinal Chemistry and Pharmaceutical Technologies Section - University of Palermo, Via Archirafi 32, 90123 Palermo, Italy. Electronic address: mariavaleria.raimondi@unipa.it.

Demetrio Raffa (D)

Department of Biological, Chemical and Pharmaceutical Sciences and Technologies (STEBICEF), Medicinal Chemistry and Pharmaceutical Technologies Section - University of Palermo, Via Archirafi 32, 90123 Palermo, Italy.

Ernest Hamel (E)

Screening Technologies Branch, Developmental Therapeutics Program, Division of Cancer Treatment and Diagnosis, Frederick National Laboratory for Cancer Research, National Cancer Institute, National Institutes of Health, Frederick, MD 21702, United States.

Fabiana Plescia (F)

Department of Biological, Chemical and Pharmaceutical Sciences and Technologies (STEBICEF), Medicinal Chemistry and Pharmaceutical Technologies Section - University of Palermo, Via Archirafi 32, 90123 Palermo, Italy. Electronic address: fabiana.plescia@unipa.it.

Marianna Lauricella (M)

Department of Biomedicine, Neurosciences and Advanced Diagnostics (BIND), Institute of Biochemistry, University of Palermo, Via del Vespro 129, 90127 Palermo, Italy.

Benedetta Maggio (B)

Department of Biological, Chemical and Pharmaceutical Sciences and Technologies (STEBICEF), Medicinal Chemistry and Pharmaceutical Technologies Section - University of Palermo, Via Archirafi 32, 90123 Palermo, Italy.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH